An Oral SARS-CoV-2 Mpro Inhibitor Clinical Candidate for the Treatment of COVID-19
Data Availability
Upon request and subject to certain criteria, conditions and exceptions, Pfizer will provide access to de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines and medical devices for indications that have been approved in the US and/or the EU or in programs that have been terminated (i.e., development of all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, requestors must enter into a data access agreement with Pfizer.
Subject Area
- Addiction Medicine (400)
- Allergy and Immunology (711)
- Anesthesia (202)
- Cardiovascular Medicine (2954)
- Dermatology (250)
- Emergency Medicine (443)
- Epidemiology (12766)
- Forensic Medicine (12)
- Gastroenterology (829)
- Genetic and Genomic Medicine (4600)
- Geriatric Medicine (420)
- Health Economics (731)
- Health Informatics (2934)
- Health Policy (1069)
- Hematology (389)
- HIV/AIDS (926)
- Medical Education (427)
- Medical Ethics (116)
- Nephrology (471)
- Neurology (4377)
- Nursing (237)
- Nutrition (640)
- Oncology (2279)
- Ophthalmology (648)
- Orthopedics (258)
- Otolaryngology (326)
- Pain Medicine (279)
- Palliative Medicine (83)
- Pathology (502)
- Pediatrics (1197)
- Primary Care Research (499)
- Public and Global Health (6963)
- Radiology and Imaging (1534)
- Respiratory Medicine (916)
- Rheumatology (442)
- Sports Medicine (385)
- Surgery (491)
- Toxicology (60)
- Transplantation (212)
- Urology (181)